Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Adrenocortical carcinoma; Advanced breast cancer; Anal cancer; Appendiceal cancer; Basal cell cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Fallopian tube cancer; Gallbladder cancer; Liver cancer; Mesothelioma; Salivary gland cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Apr 2024 Planned End Date changed from 31 Dec 2026 to 1 Jun 2027.
    • 01 Apr 2024 Planned primary completion date changed from 30 Jun 2025 to 1 Feb 2026.
    • 30 Mar 2023 Planned number of patients changed from 100 to 150.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top